Overview
BRKR market data
Price History
BRKR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 0.3% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $28.53 – $65.30 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $9B · P/B 2.91 · P/S 2.56.
Company News
Bruker Announces Expanded Strategic Collaboration With And Minority Investment In Self-Driving Labs Firm Atinary Technologies; Terms Not DisclosedBenzinga · Aug 11, 2026, 11:05 AM
Bruker shares are trading higher after the company announced a majority investment in MIMETAS to expand its post‑genomic solutions and advance drug discovery through microphysiological systems.Benzinga · Aug 10, 2026, 2:54 PM
Bruker Announces Majority Investment In Organ-On-A-Chip Developer MIMETAS, Expanding Into Microphysiological Systems For Drug Discovery; Terms Not DisclosedBenzinga · Aug 10, 2026, 11:12 AM
Citigroup Maintains Neutral on Bruker, Lowers Price Target to $53Benzinga · Aug 5, 2026, 6:51 PM
S&P 500 Hits Record Highs, Palantir Jumps 27%: Stock Market TodayBenzinga · Aug 4, 2026, 5:07 PM
Bruker shares are trading lower after the company reported mixed Q2 financial results and cut its FY26 sales guidance below estimates.Benzinga · Aug 4, 2026, 11:50 AM
Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Lowers FY2026 Sales Guidance from $3.570B-$3.600B to $3.540B-$3.570B vs $3.589B EstBenzinga · Aug 4, 2026, 11:05 AM
Bruker Q2 Adj. EPS $0.49 Beats $0.39 Estimate, Sales $838.500M Miss $853.543M EstimateBenzinga · Aug 4, 2026, 11:01 AM
Mass Spectrometry Market Size Worth USD 14.09 Billion by 2035 | SNS InsiderGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Bruker Acquires The DISQVER Clinical Metagenomics Platform From Noscendo; Financial Terms Not DisclosedBenzinga · Jul 15, 2026, 11:05 AM